Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

Cavaliere, Alessandro; Merz, Valeria; Casalino, Simona; Zecchetto, Camilla; Simionato, Francesca; Salt, Hayley Louise; Contarelli, Serena; Santoro, Raffaela; Melisi, Davide

doi:10.5230/jgc.2019.19.e39

Cited by 12 publications

(12 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was reported that the expression level of HOXB9 was a potential prognostic factor for LUAD since the upregulated HOXB9 was correlated with the advanced clinicopathological staging (28). Recent studies showed that HOXB9 was a critical transcription factor for the drug resistance of tumors, the expression silence of which would be very promising for ameliorating the resistance of tumor cells to the agent (29). However, some studies proposed a thoroughly opposite view, concluding that the downregulation of HOXB9 was correlated with the poor survival prognosis of patients bearing adenocarcinoma of the colon, ductal adenocarcinoma of the pancreas, and gastric carcinoma (30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells

Wei

2021

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths and is the primary source of brain metastases. Despite great advances in the study of the genetics and etiology of lung cancer in previous decades, the identification of the factors and mechanisms underlying the brain metastasis of lung tumors is still an open question. In this study, the results of bioinformatic conjoint analysis revealed that the metastatic microenvironment in the brain conferred lung tumor cell phenotypic plasticity, characterized by neural cell-like and embryonic–stem cell-like features. Meanwhile, the metabolic phenotype of the educated tumor cells underwent transition characterized by oxygen-related metabolism. The results of the experiments demonstrated that the downregulation of HOXB9 weakened the tumorigenicity of lung tumor cells. Bioinformatic prediction analysis also determined that many cell cycle-associated factors were potentially transcribed by HOXB9. Collectively, the results of this study suggested that under the influence of the metastatic environment of the brain, lung tumor cells seemed to acquire phenotypic plasticity characterized by neural cell-like features, and this transition may be associated with the aberrant upregulation of HOXB9.

show abstract

Section: Discussionmentioning

confidence: 99%

Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells

Wei

2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…This classification has provided a significant understanding of the molecular and heterogeneous profiles of gastric cancer across different demographics. In addition to genetic changes such as Her2neu amplification, fibroblast receptor amplification/mutation, gross factor fibroblast receptor amplification/mutation, PDL 1/PD1 pathway amplification were listed 20 , 26 . These factors have been used as prognostic as well as treatment factors.…”

Section: Discussionmentioning

confidence: 99%

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin

Aznab

Ahmadi

Khazaei

et al. 2020

IJHOSCR

View full text Add to dashboard Cite

Background: Thymidylate synthase is one of the target enzymes of 5-fluorouracil. However, the clinical and prognostic significance of TS expression in gastric cancer has remained controversial. In this study, the expression of thymidylate synthase was evaluated in gastric cancer patients treated with combinational chemotherapy; moreover, the association between TS expression and clinicopathologic characteristics and overall survival of the patients were also assessed. Materials and Methods: In this descriptive study, 89 pathological samples were gathered from patients at Kermanshah hospitals during 2008-2017. The survival status of patients was recorded and their overall survival was evaluated individually. Results: The average survival period for low and high thymidylate synthase groups was 54 and 50 months, respectively, meaning higher survival time in the lower thymidylate group. But this difference was not statistically significant (log Rank=0.88). In addition, sex, stage, recurrence, and survival had no significant difference between the low and high expression of thymidylate synthase groups (p=0.89). Conclusion: The results clearly indicated that the level of thymidylate synthase is not a significant modulator of 5- fluorouracil in gastric cancer patients. Nevertheless, evaluation of the level of the enzymes and markers as well as their effects are highly recommended for accurate selection of chemotherapeutical strategies.

show abstract

“…After a certain period of trastuzumab treatment, almost all patients will develop drug resistance even if the primary resistance is very rare in patients in HER2 overexpression. The common mechanism of trastuzumab resistance is that the selection of HER2 will not amplify clones ( Piro et al, 2018 ; Cavaliere et al, 2019 ). There are many mechanisms of primary or acquired resistance to anti-HER2 therapies, including impaired drug binding to HER2, constitutive activation of signaling pathways parallel or downstream of HER2, metabolic reprogramming or reduced immune system activation.…”

Section: Resistance In Targeted Therapymentioning

confidence: 99%

Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer

Mao

Zeng

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Pharmaceutical therapies are essential for esophageal cancer (EC). For the advanced EC, the neoadjuvant therapy regimen, including chemotherapy plus radiotherapy and/or immunotherapy, is effective to achieve clinical benefit, even pathological complete response. For the unresectable, recurrent, and metastatic EC, the pharmaceutical therapy is the limited effective regimen to alleviate the disease and prolong the progression-free survival and overall survival. In this review, we focus on the pharmaceutical applications in EC treatment including cytotoxic agents, molecular targeted antibodies, and immune checkpoint inhibitors (ICIs). The chemotherapy regimen is based on cytotoxic agents such as platinum-based complexes, fluorinated pyrimidines and taxenes. Although the cytotoxic agents have been developed in past decades, the standard chemotherapy regimen is still the cisplatin and 5-FU or paclitaxel because the derived drugs have no significant advantages of overcoming the shortcomings of side effects and drug resistance. The targeted molecular therapy is an essential supplement for chemotherapy; however, there are only a few targeted therapies available in clinical practice. Trastuzumab and ramucirumab are the only two molecular therapy drugs which are approved by the US Food and Drug Administration to treat advanced and/or metastatic EC. Although the targeted therapy usually achieves effective benefits in the early stage therapy of EC, the patients will always develop drug resistance during treatment. ICIs have had a significant impact on routine clinical practice in cancer treatment. The anti-programmed cell death-1 monoclonal antibodies pembrolizumab and nivolumab, as the ICIs, are recommended for advanced EC by several clinical trials. However, the significant issues of pharmaceutical treatment are still the dose-limiting side effects and primary or secondary drug resistance. These defects of pharmaceutical therapy restrain the clinical application and diminish the effectiveness of treatment.

show abstract

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

Cited by 12 publications

References 100 publications

Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells

Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin

Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer

Contact Info

Product

Resources

About